Briviact, a medication used to treat seizures, is an anticonvulsant that gained FDA approval in 2017 under its brand-name label [1]. As a result, its initial market exclusivity is protected, preventing generic versions from entering the market. However, patent protections for Briviact are scheduled to expire in 2029 [2].

Generic alternatives to Briviact are expected to become available once patent expirations occur, providing patients with more affordable options for treating their conditions [3]. For now, Briviact remains a brand-name medication, but future changes to patent laws or regulatory decisions may accelerate the availability of generics.

DrugPatentWatch.com provides up-to-date information on Briviact's patent status and expiration dates, as well as other medications. Please visit for more information on upcoming generic alternatives [4].

Sources:
[1] https://www.fda.gov/drugs/information-prescribers/about-fda-approved-drugs/briviact-ugam-capsules
[2] https://www.drugpatentwatch.com/drupatent/US-9765633
[3] https://www.npr.org/sections/health-shots/2020/04/27/841351213/budget-friendly-generic-medicines-face-threats-due-to-patent-changes
[4] https://www.drugpatentwatch.com